Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Warrant (NQ:SABSW)

0.0366 UNCHANGED
Streaming Delayed Price Updated: 9:35 AM EDT, Mar 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0366
Bid (Size) 0.0289 (5,500)
Ask (Size) 0.0430 (3,300)
Prev. Close 0.0366
Today's Range 0.0366 - 0.0366
52wk Range 0.0205 - 0.1800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+18.1%
+18.1%
1 Month
-8.3%
-8.3%
3 Month
+45.8%
+45.8%
6 Month
+10.9%
+10.9%
1 Year
+44.7%
+44.7%

More News

Read More
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in SAB BIO’s SAFEGUARD Clinical Trial of SAB-142 for the Treatment of Stage 3 T1D
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Highlights Data in Multiple Presentations at EASD
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Oversubscribed $175 Million Private Placement
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Reports Full Year 2024 Operating and Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO to Participate in Upcoming Investor Conferences
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
From SAB Biotherapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is SAB Biotherapeutics, Inc. - Warrant publicly traded?
Yes, SAB Biotherapeutics, Inc. - Warrant is publicly traded.
What exchange does SAB Biotherapeutics, Inc. - Warrant trade on?
SAB Biotherapeutics, Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for SAB Biotherapeutics, Inc. - Warrant?
The ticker symbol for SAB Biotherapeutics, Inc. - Warrant is SABSW on the Nasdaq Stock Market
What is the current price of SAB Biotherapeutics, Inc. - Warrant?
The current price of SAB Biotherapeutics, Inc. - Warrant is 0.0366
When was SAB Biotherapeutics, Inc. - Warrant last traded?
The last trade of SAB Biotherapeutics, Inc. - Warrant was at 03/12/26 09:35 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.